|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Howe JR, Karnell LH, Menck HR and
Scott-Conner C: The American College of Surgeons Commission on
Cancer and the American Cancer Society. Adenocarcinoma of the small
bowel: Review of the National Cancer Data Base, 1985–1995. Cancer.
86:2693–2706. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Witters LA: The blooming of the French
lilac. J Clin Invest. 108:1105–1107. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Libby G, Donnelly LA, Donnan PT, Alessi
DR, Morris AD and Evans JM: New users of metformin are at low risk
of incident cancer: A cohort study among people with type 2
diabetes. Diabetes Care. 32:1620–1625. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Landman GW, Kleefstra N, van Hateren KJ,
Groenier KH, Gans RO and Bilo HJ: Metformin associated with lower
cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care.
33:322–326. 2010. View Article : Google Scholar :
|
|
6
|
Franciosi M, Lucisano G, Lapice E,
Strippoli GF, Pellegrini F and Nicolucci A: Metformin therapy and
risk of cancer in patients with type 2 diabetes: Systematic review.
PLoS One. 8:e715832013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Noto H, Goto A, Tsujimoto T and Noda M:
Cancer risk in diabetic patients treated with metformin: A
systematic review and meta-analysis. PLoS One. 7:e334112012.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Soranna D, Scotti L, Zambon A, Bosetti C,
Grassi G, Catapano A, La Vecchia C, Mancia G and Corrao G: Cancer
risk associated with use of metformin and sulfonylurea in type 2
diabetes: A meta-analysis. Oncologist. 17:813–822. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fujita K, Iwama H, Miyoshi H, Tani J, Oura
K, Tadokoro T, Sakamoto T, Nomura T, Morishita A, Yoneyama H, et
al: Diabetes mellitus and metformin in hepatocellular carcinoma.
World J Gastroenterol. 22:6100–6113. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Miyoshi H, Kato K, Iwama H, Maeda E,
Sakamoto T, Fujita K, Toyota Y, Tani J, Nomura T, Mimura S, et al:
Effect of the antidiabetic drug metformin in hepatocellular
carcinoma in vitro and in vivo. Int J Oncol. 45:322–332.
2014.PubMed/NCBI
|
|
11
|
Kato K, Gong J, Iwama H, Kitanaka A, Tani
J, Miyoshi H, Nomura K, Mimura S, Kobayashi M, Aritomo Y, et al:
The antidiabetic drug metformin inhibits gastric cancer cell
proliferation in vitro and in vivo. Mol Cancer Ther. 11:549–560.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cai X, Hu X, Tan X, Cheng W, Wang Q, Chen
X, Guan Y, Chen C and Jing X: Metformin induced AMPK activation,
G0/G1 phase cell cycle arrest and the inhibition of growth of
esophageal squamous cell carcinomas in vitro and in vivo. PLoS One.
10:e01333492015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fujihara S, Kato K, Morishita A, Iwama H,
Nishioka T, Chiyo T, Nishiyama N, Miyoshi H, Kobayashi M, Kobara H,
et al: Antidiabetic drug metformin inhibits esophageal
adenocarcinoma cell proliferation in vitro and in vivo. Int J
Oncol. 46:2172–2180. 2015.PubMed/NCBI
|
|
14
|
Ben Sahra I, Laurent K, Loubat A,
Giorgetti-Peraldi S, Colosetti P, Auberger P, Tanti JF, Le
Marchand-Brustel Y and Bost F: The antidiabetic drug metformin
exerts an antitumoral effect in vitro and in vivo through a
decrease of cyclin D1 level. Oncogene. 27:3576–3586. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nair V, Sreevalsan S, Basha R, Abdelrahim
M, Abudayyeh A, Rodrigues Hoffman A and Safe S: Mechanism of
metformin-dependent inhibition of mammalian target of rapamycin
(mTOR) and Ras activity in pancreatic cancer: Role of specificity
protein (Sp) transcription factors. J Biol Chem. 289:27692–27701.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Janjetovic K, Harhaji-Trajkovic L,
Misirkic-Marjanovic M, Vucicevic L, Stevanovic D, Zogovic N,
Sumarac-Dumanovic M, Micic D and Trajkovic V: In vitro and in vivo
anti-melanoma action of metformin. Eur J Pharmacol. 668:373–382.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhou XZ, Xue YM, Zhu B and Sha JP: Effects
of metformin on proliferation of human colon carcinoma cell line
SW-480. Nan Fang Yi Ke Da Xue Xue Bao. 30:1935–1938. 19422010.In
Chinese.
|
|
18
|
Kourelis TV and Siegel RD: Metformin and
cancer: New applications for an old drug. Med Oncol. 29:1314–1327.
2012. View Article : Google Scholar
|
|
19
|
Zhou JY, Xu B and Li L: A new role for an
old drug: Metformin targets microRNAs in treating diabetes and
cancer. Drug Dev Res. 76:263–269. 2015. View Article : Google Scholar
|
|
20
|
Laemmli UK: Cleavage of structural
proteins during the assembly of the head of bacteriophage T4.
Nature. 227:680–685. 1970. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Towbin H, Staehelin T and Gordon J:
Electrophoretic transfer of proteins from polyacrylamide gels to
nitrocellulose sheets: Procedure and some applications. Proc Natl
Acad Sci USA. 76:4350–4354. 1979. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
D'Incalci M, Colombo T, Ubezio P,
Nicoletti I, Giavazzi R, Erba E, Ferrarese L, Meco D, Riccardi R,
Sessa C, et al: The combination of yondelis and cisplatin is
synergistic against human tumor xenografts. Eur J Cancer.
39:1920–1926. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Benjamini Y and Hochberg Y: Controlling
the false discovery rate: A practical and powerful approach to
multiple testing. J R Stat Soc B. 57:289–300. 1995.
|
|
24
|
Abbas T and Dutta A: p21 in cancer:
Intricate networks and multiple activities. Nat Rev Cancer.
9:400–414. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Masaki T, Shiratori Y, Rengifo W, Igarashi
K, Yamagata M, Kurokohchi K, Uchida N, Miyauchi Y, Yoshiji H,
Watanabe S, et al: Cyclins and cyclin-dependent kinases:
Comparative study of hepatocellular carcinoma versus cirrhosis.
Hepatology. 37:534–543. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhou G, Myers R, Li Y, Chen Y, Shen X,
Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, et al: Role of
AMP-activated protein kinase in mechanism of metformin action. J
Clin Invest. 108:1167–1174. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zakikhani M, Dowling RJ, Sonenberg N and
Pollak MN: The effects of adiponectin and metformin on prostate and
colon neoplasia involve activation of AMP-activated protein kinase.
Cancer Prev Res (Phila). 1:369–375. 2008. View Article : Google Scholar
|
|
28
|
Zakikhani M, Dowling R, Fantus IG,
Sonenberg N and Pollak M: Metformin is an AMP kinase-dependent
growth inhibitor for breast cancer cells. Cancer Res.
66:10269–10273. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gwak H, Kim Y, An H, Dhanasekaran DN and
Song YS: Metformin induces degradation of cyclin D1 via AMPK/GSK3β
axis in ovarian cancer. Mol Carcinog. 56:349–358. 2017. View Article : Google Scholar
|
|
30
|
Sesen J, Dahan P, Scotland SJ, Saland E,
Dang VT, Lemarié A, Tyler BM, Brem H, Toulas C, Cohen-Jonathan
Moyal E, et al: Metformin inhibits growth of human glioblastoma
cells and enhances therapeutic response. PLoS One. 10:e01237212015.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang LW, Li ZS, Zou DW, Jin ZD, Gao J and
Xu GM: Metformin induces apoptosis of pancreatic cancer cells.
World J Gastroenterol. 14:7192–7198. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Rattan R, Graham RP, Maguire JL, Giri S
and Shridhar V: Metformin suppresses ovarian cancer growth and
metastasis with enhancement of cisplatin cytotoxicity in vivo.
Neoplasia. 13:483–491. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ben Sahra I, Regazzetti C, Robert G,
Laurent K, Le Marchand-Brustel Y, Auberger P, Tanti JF,
Giorgetti-Peraldi S and Bost F: Metformin, independent of AMPK,
induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer
Res. 71:4366–4372. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang L, Xiao J, Gu W and Chen H: Sex
difference of Egfr expression and molecular pathway in the liver:
Impact on drug design and cancer treatments? J Cancer. 7:671–680.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Engel BJ, Bowser JL, Broaddus RR and
Carson DD: MUC1 stimulates EGFR expression and function in
endometrial cancer. Oncotarget. 7:32796–32809. 2016.PubMed/NCBI
|
|
36
|
Perry JE, Grossmann ME and Tindall DJ:
Epidermal growth factor induces cyclin D1 in a human prostate
cancer cell line. Prostate. 35:117–124. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Huang J, Fan X, Wang X, Lu Y, Zhu H, Wang
W, Zhang S and Wang Z: High ROR2 expression in tumor cells and
stroma is correlated with poor prognosis in pancreatic ductal
adenocarcinoma. Sci Rep. 5:129912015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lu C, Wang X, Zhu H, Feng J, Ni S and
Huang J: Over-expression of ROR2 and Wnt5a cooperatively correlates
with unfavorable prognosis in patients with non-small cell lung
cancer. Oncotarget. 6:24912–24921. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sun B, Ye X, Lin L, Shen M and Jiang T:
Up-regulation of ROR2 is associated with unfavorable prognosis and
tumor progression in cervical cancer. Int J Clin Exp Pathol.
8:856–861. 2015.PubMed/NCBI
|
|
40
|
O'Connell MP, Fiori JL, Xu M, Carter AD,
Frank BP, Camilli TC, French AD, Dissanayake SK, Indig FE, Bernier
M, et al: The orphan tyrosine kinase receptor, ROR2, mediates Wnt5A
signaling in metastatic melanoma. Oncogene. 29:34–44. 2010.
View Article : Google Scholar :
|
|
41
|
Henry CE, Llamosas E, Djordjevic A, Hacker
NF and Ford CE: Migration and invasion is inhibited by silencing
ROR1 and ROR2 in chemoresistant ovarian cancer. Oncogenesis.
5:e2262016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lyros O, Nie L, Moore T, Medda R, Otterson
M, Behmaram B, Mackinnon A, Gockel I, Shaker R and Rafiee P:
Dysregulation of WNT5A/ROR2 signaling characterizes the progression
of Barrett's-associated esophageal adenocarcinoma. Mol Cancer Res.
14:647–659. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Morishita A and Masaki T: miRNA in
hepatocellular carcinoma. Hepatol Res. 45:128–141. 2015. View Article : Google Scholar
|
|
44
|
Xu K, Liang X, Cui D, Wu Y, Shi W and Liu
J: miR-1915 inhibits Bcl-2 to modulate multidrug resistance by
increasing drug-sensitivity in human colorectal carcinoma cells.
Mol Carcinog. 52:70–78. 2013. View Article : Google Scholar
|
|
45
|
Nakazawa K, Dashzeveg N and Yoshida K:
Tumor suppressor p53 induces miR-1915 processing to inhibit Bcl-2
in the apoptotic response to DNA damage. FEBS J. 281:2937–2944.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Roy S, Yu Y, Padhye SB, Sarkar FH and
Majumdar APN: Difluorinated-curcumin (CDF) restores PTEN expression
in colon cancer cells by down-regulating miR-21. PLoS One.
8:e68542013. View Article : Google Scholar
|
